In this episode, we hear from Mark Wuttke, CEO of Dopavision. In their own words, Dopavision is pioneering the development of innovative solutions that target the eye’s innate dopamine pathway to address unmet needs in ophthalmology using digitally delivered light. 
Topics include:

The background to Dopavision

The pediatric Myopia vs adult Myopia markets

Patient experience using Dopavision

Changes to clinical trials and the mechanism of action

Plans for commercialization

Potential future applications to other ophthalmological conditions and neurological conditions 

The future of OTC vs Rx


Guest Links and Resources:

Connect with Mark Wuttke on LinkedIn


Visit Dopavision


Listen to Digital Therapeutics for Pediatrics, Oncology and Managing Pain with Francesca Wuttke

Episode PDF


Host Links:

Connect with Eugene Borukhovich: Twitter | LinkedIn


Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn


Connect with YourCoach.health: Website | Twitter


Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App


HealthXL: Website | Twitter | Join an Event




Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to:
> Presenting Partner: Amalgam Rx
> Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health

Follow Digital Health Today:
Browse Episodes | Twitter | LinkedIn | Facebook | Instagram

Follow Health Podcast Network:
Browse Shows | LinkedIn | Twitter | Facebook | Instagram

Ver todos los episodios